» Authors » Phillip Parente

Phillip Parente

Explore the profile of Phillip Parente including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 832
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Chui W, Gurrala S, Hosking P, Wong P, Parente P, Sengupta S
Urol Case Rep . 2024 Jul; 55:102768. PMID: 38978996
We describe a unique presentation of acute lower limb ischaemia due to metastatic seminoma in a middle-aged man with a large retroperitoneal mass. The patient underwent vascular bypass surgery of...
2.
Zhong Y, Anton A, Xie O, Tan N, OHaire S, Maleki S, et al.
JCO Oncol Pract . 2024 May; 20(9):1231-1242. PMID: 38805663
Purpose: Androgen receptor pathway inhibitors (ARPIs) are widely prescribed in metastatic castration-resistant prostate cancer (mCRPC). Real-world frequencies and potential impacts of comorbidities and concomitant medication (conmed) interactions with ARPIs are...
3.
Fernando M, Anton A, Weickhardt A, Azad A, Uccellini A, Brown S, et al.
J Geriatr Oncol . 2023 Sep; 14(8):101621. PMID: 37683368
Introduction: Prostate cancer (PC) is the second commonest malignancy and fifth leading cause of cancer death in men worldwide. Older men are more likely to develop PC but are underrepresented...
4.
Huang J, Faisal W, Brand M, Smith S, Alexander M, Briggs L, et al.
Med J Aust . 2023 Jun; 219(3):120-126. PMID: 37365486
Objectives: To report stage-specific patterns of treatment and the influence of management and treatment type on survival rates for people newly diagnosed with small cell lung cancer (SCLC). Design: Cross-sectional...
5.
Collins I, Blum R, Segelov E, Parente P, Underhill C
Intern Med J . 2023 Jun; 53(6):1094. PMID: 37349277
No abstract available.
6.
Collins I, Blum R, Segelov E, Parente P, Underhill C
Intern Med J . 2022 Dec; 53(6):946-950. PMID: 36571397
Background: Cancer incidence is growing, with increasing treatment options and durations. This has led to an increase workload on the current oncology workforce. The global pandemic has increased this pressure...
7.
Pereira-Salgado A, Anton A, Franchini F, Mahar R, Kwan E, Wong S, et al.
Expert Rev Pharmacoecon Outcomes Res . 2022 Dec; 23(2):231-239. PMID: 36541133
Introduction: Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) remain unclear. Material And Methods: Data from the electronic Castration-resistant Prostate cancer Australian Database...
8.
Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, et al.
BJU Int . 2022 Nov; 131(2):179-182. PMID: 36371671
No abstract available.
9.
Soo W, King M, Pope A, Parente P, Darzins P, Davis I
Lancet Healthy Longev . 2022 Sep; 3(9):e617-e627. PMID: 36102776
Background: The effectiveness of comprehensive geriatric assessment (CGA) in improving health outcomes in cancer settings is unclear. We evaluated whether CGA can improve health-related quality of life (HRQOL) in older...
10.
Soo W, King M, Pope A, Steer C, Devitt B, Chua S, et al.
Lancet Healthy Longev . 2022 Sep; 2(1):e24-e33. PMID: 36098126
Background: Functional assessment of patients with cancer can be challenging and is often undertaken by the clinician with minimal direct input from the patient. We developed and aimed to validate...